Expert Interview
Discussing Structure Therapeutics Report of Positive Topline Data from ACCESS Program for its Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron
Ticker(s): GPCRInstitution: Yale School of Medicine
- Endocrinologist specializing in diabetes, obesity, and sleep disorders, with board certifications in internal medicine, endocrinology, and sleep medicine.
- Assistant Professor researching the interplay of obesity, diabetes, and sleep apnea, with over eight publications on glucose regulation and SGLT2 inhibitors.
- Directs obesity medicine and weight management programs, integrating novel pharmacotherapies for chronic disease management.
Based on what you’ve seen so far, how would you assess the efficacy signals of aleniglipron relative to currently approved GLP-1s?
Added By: nick_adminWhere could you see aleniglipron fitting into the current obesity treatment algorithm?
Added By: nick_adminOn a scale of 1–10, how promising do you find aleniglipron’s potential based on current data?
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
